Calls for proposals
Governing Board Evaluation Dates
The Governing Board members will meet twice during 2019 to review new proposals. Proposals need to be submitted 6 weeks prior to the GB evaluation date.
- 2nd April
- 10th October
Call open all year.
Please visit "Submit project Proposal”, where you will find the documents we are asking you to complete to apply for a TCOLF grant.
CALL OPEN FOR ENVIRONMENTAL ENTERIC DYSFUNCTION (EED) DRUG DISCOVERY
IN ADDITION TO TUBERCULOSIS, MALARIA, KINETOPLASTIDS AND ENTERIC INFECTIONS, The Tres Cantos Open Lab Foundation invites applications for projects with a focus on prevention and/or treatment of EED
BACKGROUND: EED, an incompletely defined subclinical inflammatory disorder of the small intestine, is emerging as one of the underlying cause of stunting and may explain at least 40% of all cases of stunting even after controlling for diarrhoea and is associated with reduced efficacy of enteric vaccines in developing countries. The condition, is thought to be a result of living in unsanitary conditions, under-nutrition and ingestion of faecal bacteria and is characterized by the flattening of villi, increase in crypt depth, reduction of absorptive capacity of the small intestine and reduced barrier function resulting in bidirectional leakage of fluid, bacteria and toxins across the gut wall.1,2
SCIENTIFIC OPPORTUNITY: Current health and nutrition programmes are having a limited impact to mitigate EED effects. TCOLF is looking for innovative opportunities to complement these strategies. These opportunities include but are not limited to pre/pro-biotics, hits/leads and drug assets (marketed or in development) that exploit the pathophysiology of EED.
About this call—Key areas of interest:
- Exploitation of new targets towards EED treatment
- Phenotypic in vitro assays that allow identification of hits (single cell, co-culture, organoids, etc)
- Medicinal chemistry optimisation of hits/leads
- Animal models that allow evaluation and establishment of PK/PD relationships
- Biopharmaceutical/microbiome-based approaches
More information about TCOLF
Ballell, L. et al. Nat Rev Drug Discov, 15, 292 (2016)
The Tres Cantos Open Lab Foundation (TCOLF) mission
To enable translation of innovative research in Diseases of the Developing World through collaborations where the complementary expertise and capacity currently residing in the Pharmaceutical Industry is made accessible to Academic, Biotech and other Pharmaceutical Industry scientists.
Collaborative projects between a “Home institution”, i.e. public or private research institutes, high education institutions or pharmaceutical companies working in the research areas supported by TCOLF, and the “Host institution”, which is GSK R&D Global Heath unit. Projects can be implemented entirely at the GSK R&D site in Tres Cantos (Spain), or at both the Home and the Host Institution facilities; respective timelines must be consistent with the expertise and resources available at each site. Typically, the Foundation expects that the project duration will range from 6 to 24 months.
TCOLF funding will cover the personnel costs of the visiting scientist(s), salary and relocation, and the travel expenses. Other costs such as lab consumables, research services, conference fees, etc. will be
Intellectual Property Rights (IPR)
In accordance with the Guiding Principles of WIPO Research, so that IP output is made available royalty free for neglected diseases treatment/research. The Principles will be part of the Agreement to be signed in case of selection.
How to apply
Call open all year. During 2019, proposals will be reviewed in April and October. To apply, In no more than 500 words, describe your idea and send to email@example.com
Figure: Epithelial Colon Cancer cells showing presence (left) and absence (right) of tight junction protein, Zonulin 1 (ZO1) in Green
1Mahfuz, M et al. 10.1136/bmjopen-2017- 017768
2Owino, V. et al. 10.1542/peds.2016-0641